BRIEF-Valeant Pharmaceuticals Q1 adjusted non-gaap EPS $1.27
June 7 (Reuters) - Valeant Pharmaceuticals International Inc :
* Updating its full year 2016 guidance
* FY adjusted ebitda (non-gaap) is expected to be in range of $4.80 - $4.95 billion
* FY 2016 earnings per share view $8.46, revenue view $10.86 billion -- Thomson Reuters I/B/E/S
* "We have made progress toward stabilizing organization over past few months"
* While we recognize that we did not meet timeline for filing Q1 results, with filing expected this week, we will be current in our financial reporting
* "Expect to file our financial results in a timely manner going forward"
* "There are some challenges to work through in certain business operations in 2016, such as our u.s. Dermatology unit"
* Full year 2016 total revenue guidance updated from previous guidance of $11.0 - $11.2 billion Continued...